Joseph Zibrak
Pulmonary Disease · Boston, MANPI 1689655714
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (42.8%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Boehringer Ingelheim at 59.7% of the total. Reporting peaked in 2019 at $49,202 and has fallen 91.9% since, to $3,967 in 2023. Among pulmonary disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 87 payments — averaging $875.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$45K
- F. Hoffmann-la Roche AG$18K
- Daiichi Sankyo Inc.$7K
- Genentech USA, Inc.$5K
- Genentech, Inc.$71
- United Therapeutics Corporation$18
Across 37 payments — averaging $3154.81 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$53K
- Roche Products Limited$41K
- F. Hoffmann-la Roche AG$16K
- Boehringer Ingelheim International GmbH$8K
- Boehringer Ingelheim Limited$117
What the payments were for
- Consulting fees$27,61836%
- Speaking & faculty fees$32,56943%
- Travel & lodging$13,74018%
- Food & beverage$2,1243%
- Education$980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 59 | $45,487 |
| F. Hoffmann-la Roche AG | 7 | $18,459 |
| Daiichi Sankyo Inc. | 9 | $6,678 |
| Genentech USA, Inc. | 9 | $5,436 |
| Genentech, Inc. | 2 | $71 |
| United Therapeutics Corporation | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$76,148 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 22 | $283,401 |
| Pirfenidone | 15 | $65,531 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $19,056 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $13,556 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $6,757 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $6,743 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 11 | $5,925 |
| Serevent DiskusSalmeterol Xinafoate | 13 | $5,277 |
| Advair DiskusFluticasone Propion/Salmeterol | 12 | $2,225 |
| Montelukast Sodium | 40 | $753 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 21 | $600 |
| Ipratropium Bromide | 12 | $286 |
| Azithromycin | 13 | $113 |
| Prednisone | 11 | $49 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $45,487 | $290,15933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Other pulmonary disease in Boston
- Erik FolchBoston$543K
- Bartolome CelliBoston$536K
- Adnan MajidBoston$351K
- Nicholas HillBoston$293K
- Harrison FarberBoston$190K
- Tufik AssadBoston$132K
- Anthony FaugnoBoston$132K
- Hyun KimBoston$117K
- George WashkoBoston$101K
- Aaron WaxmanBoston$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.